Baird Starts Editas Medicine (EDIT) at Underperform, Sees More than 50% Downside
Tweet Send to a Friend
(Updated - November 3, 2020 8:31 AM EST)(updated to add analyst comments)Baird analyst Madhu Kumar initiates coverage on Editas Medicine ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
